A Multicenter, 6-month, Open-label Safety Study of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors Sucampo Pharma AG
- 23 Dec 2016 Status changed from active, no longer recruiting to completed.
- 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 12 May 2016 New trial record